Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.132
Neutral
RSI(14)
44.795
Neutral
STOCH(KDJ)(9,3,3)
18.293
Neutral
ATR(14)
0.246
Low Volatility
CCI(14)
-122.259
Sell
Williams %R
80.000
Oversold
TRIX(12,20)
-0.086
Sell
StochRSI(14)
61.082
Buy
AC Immune SA
ACIU3.140USD
+0.180+6.08%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
315.29MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of AC Immune SA
Currency: USD Updated: 2026-02-06Key Insights
AC Immune SA's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 152 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
AC Immune SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
AC Immune SA Highlights
StrengthsRisks
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 631.15% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.97M.
Fairly Valued
The company’s latest PE is -3.50, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 24.95M shares, increasing 0.03% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 5.57K shares of this stock.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
9.000
Target Price
+194.12%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of AC Immune SA is 5.17, ranking 379 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.16M, representing a year-over-year decrease of 96.08%, while its net profit experienced a year-over-year decrease of 406.91%.
Score
Financials
4.99
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.83
Operational Efficiency
2.83
Growth Potential
3.14
Shareholder Returns
7.07
AC Immune SA's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of AC Immune SA is 5.95, ranking 349 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.50, which is -41.69% below the recent high of -2.04 and -126.40% above the recent low of -7.91.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 152/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of AC Immune SA is 9.50, ranking 4 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.50, with a high of 12.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Strong Buy
Current Rating
9.000
Target Price
+194.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
AC Immune SA
ACIU
4
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of AC Immune SA is 6.88, ranking 144 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.71 and the support level at 2.76, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.154
Sell
MA10
3.285
Sell
MA20
3.417
Sell
MA50
3.214
Sell
MA100
3.171
Sell
MA200
2.581
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of AC Immune SA is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 29.05%, representing a quarter-over-quarter decrease of 0.04%. The largest institutional shareholder is James Simons, holding a total of 770.42K shares, representing 0.77% of shares outstanding, with 4.11% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BVF Partners L.P.
DH Capital GmbH & Co. KG
Varuma AG
Affiris AG
Pfeifer (Andrea M. A Ph.D.)
Wells Fargo Advisors
Millennium Management LLC
Acadian Asset Management LLC
BlackRock Institutional Trust Company, N.A.
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of AC Immune SA is 1.90, ranking 272 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.63. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.62
VaR
+6.46%
240-Day Maximum Drawdown
+43.08%
240-Day Volatility
+87.73%
Return
Best Daily Return
60 days
+15.41%
120 days
+27.48%
5 years
+71.72%
Worst Daily Return
60 days
-10.64%
120 days
-11.98%
5 years
-19.18%
Sharpe Ratio
60 days
+0.10
120 days
+1.34
5 years
+0.15
Risk Assessment
Maximum Drawdown
240 days
+43.08%
3 years
+70.40%
5 years
+82.32%
Return-to-Drawdown Ratio
240 days
+0.48
3 years
+0.20
5 years
-0.13
Skewness
240 days
+1.12
3 years
+4.64
5 years
+3.49
Volatility
Realised Volatility
240 days
+87.73%
5 years
+89.01%
Standardised True Range
240 days
+6.24%
5 years
+7.64%
Downside Risk-Adjusted Return
120 days
+246.92%
240 days
+246.92%
Maximum Daily Upside Volatility
60 days
+72.64%
Maximum Daily Downside Volatility
60 days
+47.15%
Liquidity
Average Turnover Rate
60 days
+0.13%
120 days
+0.14%
5 years
--
Turnover Deviation
20 days
-53.52%
60 days
-43.85%
120 days
-38.73%
Peer Comparison
Biotechnology & Medical Research
AC Immune SA
ACIU
5.95 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
